Shian-Huey is a drug discovery leader with over 15 years of biopharma industry experience. Her expertise spans numerous disease areas — including metabolic diseases, muscular dystrophies, immunology, neurodegenerative diseases, fibrosis and cancer — and multiple modalities including small molecules, biologics and RNA therapeutics. Prior to joining Paratus, Shian-Huey was VP, Discovery Biology at Ananke Therapeutics, where she led the discovery biology team on RNA structure/function platform development and computational biology.
Previously she spent over 8 years in roles of increasing responsibility at Pfizer, including as a project leader on an inflammatory disease program — which she oversaw from lead identification to IND filing and Phase 1 initiation — and culminating in the role of Director, Head of Emerging Science Biology within the Emerging Science & Innovation (ES&I) team, where she led the team for early stage target discovery in numerous disease areas. Her previous experience includes roles at GSK in muscle metabolism and the University of Michigan Life Sciences Institute studying metabolic diseases. Shian-Huey holds a B.S. in agricultural chemistry from National Taiwan University, an M.S. in biochemistry from National Yang Ming University, and a Ph.D. in cell and molecular biology from the University of Michigan.